Compositions and methods for treating wounds
Patent Information
- Application Number
- JP2023527441
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-08
- Filing Date
- 2021-12-07
- Publication Date
- 2024-11-06
AI Technical Summary
Chronic wounds, particularly diabetic foot ulcers, pose a significant health challenge due to inadequate treatment options, leading to high costs and increased amputations, with collagen and elastin playing crucial roles in wound healing but being severely lacking in adult wound healing.
Topical application of polypeptides with sequences similar to SEQ ID NO: 1 or 2, or their derivatives, in a suitable vehicle for transdermal delivery, to promote wound healing by enhancing collagen and elastin production, improving wound closure, contraction, and re-epithelialization.
The polypeptides significantly accelerate wound healing by increasing collagen and elastin production, reducing residual wound area, and enhancing wound contraction and re-epithelialization rates in diabetic impaired healing models.
Abstract
Description
[Technical Field]
[0001] Cross-reference with related applications This application claims priority to U.S. Provisional Patent Application No. 63 / 122,746, filed on 8 December 2020, the contents of which are incorporated herein by reference in their entirety. [Background technology]
[0002] Wound healing is a dynamic process involving many factors and cell types, including blood cells, fibroblasts, endothelial cells, and extracellular matrix components such as collagen and elastin. Normal wound healing can be divided into several sequential stages that overlap spatially and temporally: homeostasis maintenance, inflammation, granulation tissue formation, and tissue remodeling. Skin injury triggers a complex wound healing process involving the organization of cells, matrix components, and signaling factors that re-establish the skin's barrier function. This phenomenon is characterized by the attenuation of the inflammatory response, differences in signaling factor expression, and the regeneration of normal skin structure. Several proteins, including collagen and elastin, have been shown to play crucial roles in wound healing.
[0003] Collagen assists the body's natural healing process by preparing the wound bed, balancing wound chemistry, inducing cell migration and growth, inducing granulation tissue, and improving overall skin strength. The role of collagen in these various chemical, mechanical, and biological factors creates an environment that promotes wound healing, ultimately leading to wound closure. During injury and wound repair, collagen binds to fibronectin and specific receptor sites on platelet membranes, releasing substances that induce platelet adhesion and aggregation, initiating hemostasis. Furthermore, it acts as a chemotactic factor for monocytes and leukocytes, promoting autolysis in wound healing by utilizing enzymes and water in the body to rehydrate and liquefy inactivated tissue. Additionally, collagen supports the growth of new capillaries and directly supports the growth, attachment, differentiation, and migration of keratinocytes to the site of injury. Studies have shown that adding collagen to injured animals accelerates the wound healing process, suggesting it may be a potentially beneficial therapeutic agent in wound clinics in the future.
[0004] Elastin imparts various mechanical and cellular interaction properties to the skin. In adult wound healing, elastin is significantly deficient, and after scar formation, only a disordered network of elastic fibers remains. Due to its inherent properties, elastin is a desirable component for adult wound healing. Elastin provides resilience and resistance, and induces various cellular activities such as cell migration and proliferation, matrix synthesis, and protease production.
[0005] Chronic wounds develop as a result of dysregulation of one or more complex molecular and biological events involved in proper healing. Chronic wounds in diabetic patients are one of the most common complications in the United States, affecting millions of people annually, and often costing billions of dollars to the healthcare system due to inadequate treatment options. Chronic wounds, particularly diabetic foot ulcers, are extremely costly for those who suffer from them, with $25 billion spent annually on treatment. Despite chronic wounds not being an uncommon problem, affecting 9 to 12 million people, the supply of wound care products is limited, resulting in an increase in amputations and further costs for the healthcare system and patients. Wound healing and treatment remain a major health challenge, consuming significant medical resources to improve patients' quality of life. [Overview of the Initiative]
[0006] Compositions and methods for treating wounds in subjects requiring such treatment are provided. The compositions herein contain a polypeptide according to sequence ID number: 1 or 2, or a derivative or analog thereof, in a vehicle suitable for transdermal delivery of the polypeptide. The method comprises administering a composition containing a polypeptide according to sequence ID number: 1 or 2, or a derivative or analog thereof, to a subject in a vehicle suitable for transdermal delivery of the polypeptide to a wound site. A wound site refers to a chronic wound, abrasion, cut, burn, or site of a surgical procedure such as a skin graft. In one embodiment, the polypeptide has at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity with respect to the amino acid sequence described in sequence ID number: 1 or 2.
[0007] The compositions herein may be administered to the wounded skin and / or local wound cavity of a patient as a prophylactic or therapeutic administration, or as a cosmetic for skin use, and may optionally be delivered by a moist dressing. [Brief explanation of the drawing]
[0008] [Figure 1] Figure 1 shows that treatment with a topical composition containing sequence ID number:1 had a positive effect on wound closure compared to vehicle control treatment in a db / db diabetic impaired healing animal model, as measured by the percentage of wound area remaining at 4, 8, 12, 16, 20, and 24 days post-wound. [Figure 2] Figure 2 shows that the topical composition containing sequence ID number:1 was found to have a positive effect on wound shrinkage compared to the vehicle control treatment in the db / db diabetic impaired healing animal model, as measured by the percentage of wound shrinkage at 4, 8, 12, 16, 20, and 24 days post-wound. [Figure 3] Figure 3 shows that the topical composition containing sequence ID number:1 was found to have a positive effect on wound reepithelialization compared to vehicle-controlled treatment, as measured by the wound reepithelialization rate at 4, 8, 12, 16, 20, and 24 days post-wound in a db / db diabetic impaired healing animal model. [Figure 4] Figure 4 shows that topical compositions containing sequence ID number:1 (in different dose regimens) were found to have a positive effect on wound closure compared to vehicle-controlled treatment in a db / db diabetic impaired healing animal model, as measured by the percentage of residual wound area at 4, 8, 12, and 16 days post-wound. [Figure 5] Figure 5 shows that topical compositions containing sequence ID number:1 (in different dose regimens) were found to have a positive effect on wound shrinkage compared to vehicle-controlled treatment in a db / db impaired diabetic healing animal model, as measured by the percentage of wound shrinkage at 4, 8, 12, and 16 days post-injury. [Figure 6] Figure 6 shows that topical compositions containing sequence ID number:1 (in different dose regimens) were found to have a positive effect on wound reepithelialization compared to vehicle-controlled treatment, as measured by the wound reepithelialization rates at 4, 8, 12, and 16 days post-wound in a db / db diabetic impaired healing animal model. [Figure 7]Figure 7 shows that compositions containing sequence ID number 1 or 2 promote wound healing by increasing collagen production by keratinocytes. [Modes for carrying out the invention]
[0009] The following detailed descriptions are provided to assist those skilled in the art in carrying out the compositions and methods disclosed herein, but should not be construed as limiting, as modifications and variations of the embodiments disclosed herein can be made by those skilled in the art without departing from the scope and spirit of this disclosure. All publications and other documents referenced herein are incorporated herein by reference in their entirety. In the event of any conflict between the subject matter incorporated by reference and the subject matter disclosed herein, the subject matter of this disclosure shall prevail.
[0010] The following terms are used in this disclosure to describe different aspects of the compositions and methods disclosed herein. These terms are for illustrative purposes only.
[0011] As used herein, “effective dose” refers to the amount of the active ingredient that is effective in promoting healing and wound closure when administered to a subject. In one embodiment, the effective dose of a topical composition containing sequence ID number: 1 or 2 is an amount in the range of about 0.1 μg / mL to about 10 μg / mL and all values in between. Alternatively, the effective dose of a topical composition containing sequence ID number: 1 or 2 is an amount in the range of about 0.01% w / v to about 10% w / v and all values in between.
[0012] As used herein, "formulation" or "composition" refers to a solution, cream, ointment, paste, lotion, balm, foam, spray, transdermal patch, or gel (interchangeable) containing an effective amount of an active ingredient, prepared to be suitable for administration to a wound site. If necessary, the formulation can contain pharmaceutically acceptable carriers, excipients, and / or one or more additives. Suitable additives are, for example, viscosity agents, antioxidants (e.g., ascorbic acid, methionine), coloring agents, preservatives, stabilizers, buffers, chelating agents (e.g., EDTA), binders, bactericides, humectants, hyaluronic acid, antibacterial agents, anti-inflammatory and / or antifungal agents. The formulations disclosed herein can contain other active ingredient(s) in combination with the active ingredients described herein.
[0013] As used in this example, "IMG-1T" means a composition containing a polypeptide (the "active ingredient") according to SEQ ID NO: 1 or 2.
[0014] As used herein, SEQ ID NO: 1 refers to a 293 - amino acid polypeptide containing the following sequence: MADDAGAAGGPGGPGGPGMGNRGGFRGGFGSGIRGRGRGRGRGRGRGRGARGGKAEDKEWMPVTKLGRLVKDMKIKSLEEIYLFSLPIKESEIIDFFLGASLKDEVLKIMPVQKQTRAGQRTRFKAFVAIGDYNGHVGLGVKCSKEVATAIRGAIILAKLSIVPVRRGYWGNKIGKPHTVPCKVTGRCGSVLVRLIPAPRGTGIVSAPVPKKLLMMAGIDDCYTSARGCTATLGNFAKATFDAISKTYSYLTPDLWKETVFTKSPYQEFTDHLVKTHTRVSVQRTQAPAVATT
[0015] As used herein, SEQ ID NO: 2 refers to a 159 - amino acid polypeptide containing the following sequence: GHVGLGVKCSKEVATAIRGAIILAKLSIVPVRRGYWGNKIGKPHTVPCKVTGRCGSVLVRLIPAPRGTGIVSAPVPKKLLMMAGIDDCYTSARGCTATLGNFAKATFDAISKTYSYLTPDLWKETVFTKSPYQEFTDHLVKTHTRVSVQRTQAPAVATT
[0016] Contemplated herein are pharmaceutically acceptable salt forms of SEQ ID NO: 1 or 2. Contemplated herein are derivatives of SEQ ID NO: 1 or 2. In general, derivatives of SEQ ID NO: 1 or 2 include, for example, fragments, one or more conservative amino acid substitutions, chemically modified amino acids, and the like. Fragments of SEQ ID NO: 1 include, for example, 1 M- 134 N, 135 G- 201 D, 135 G- 293 T, 161 S- 235 N, and the like. Conservative amino acid substitutions contemplated herein include, for example, substituting serine (S) with threonine (T), cysteine (C) with serine (S), lysine (K) with arginine, and the like. See, for example, Table 1 of WO9957141A1. Derivatives of SEQ ID NO: 1 include, for example, an acylated (e.g., RC(O)-, where R is C1-C 16 alkyl, e.g., methyl) lysinyl moiety (e.g., 54 K, 58 K, 65 K, 71 K, 263 K, 275 K, etc.), a phosphorylated serinyl or tyrosinyl moiety (e.g., 264 S, 270 T, 281 S, etc.).
[0017] As used herein, "subject" or "individual" or "animal" or "patient" or "mammal" refers to any subject for which diagnosis, prognosis or treatment is desired, particularly a mammalian subject.
[0018] As used herein, the terms “treat,” “administer,” or “treat,” and other grammatical equivalents include alleviating, reducing, or improving the symptoms of a disease or condition; preventing additional symptoms; improving or preventing the underlying metabolic cause of symptoms; inhibiting a disease or condition, e.g., preventing the onset of a disease or condition; alleviating a disease or condition; causing regression of a disease or condition; alleviating a condition caused by a disease or condition; or stopping the symptoms of a disease or condition; and prevention. The terms further include achieving therapeutic and / or preventive benefits. A therapeutic benefit means the eradication or improvement of the underlying disease being treated. A therapeutic benefit is also achieved by the eradication or improvement of one or more physiological symptoms associated with an underlying disease, such that improvement is observed in the patient, even though the patient may still be suffering from the underlying disease. For a preventive benefit, a composition may be administered to a patient at risk of developing a particular disorder, or to a patient reporting one or more physiological symptoms, even if no diagnosis has been made.
[0019] As used herein, “therapeutic dose” means the amount of active ingredient that can achieve a clinically relevant endpoint in a patient or patient population.
[0020] In this specification, “wound” means damage or destruction of one or more layers of protective function of the skin, and is intended to mean loss of epithelial continuity, whether or not the underlying connective tissue (i.e., muscle, bone, nerve) is lost, after the skin or the tissue / organ beneath it has been damaged by one or more factors, such as lacerations, cuts, abrasions, surgical procedures, burns (including chemical burns), friction / shearing forces, pressure, or diseases such as diabetic ulcers or carcinomas.
[0021] Examples The following information is illustrative of the embodiments of the pharmaceutical compositions disclosed herein and their use for the treatment of wounds in mammals (e.g., humans), and should not be considered to limit the subject matter claimed herein.
[0022] Example 1 Diabetic patients are prone to impaired wound healing, and foot ulcers are a prime example. Furthermore, spontaneously diabetic (db / db) mice (i.e., BKS.Cg-m Dock7) m + / +Lepr db Delayed wound healing is observed in certain diabetic animals, including J mice.
[0023] In this exemplary study, we investigated the effects of two concentrations of topically applied IMG-1T (in 0.5% HPMC) on the repair of full-thickness excised skin wounds in this impaired healing model. Wound healing with administration of IMG-1T (2.0 and 4.0 μg / mL) in 0.5% HPMC was examined and compared to the healing of similar wounds exposed to a control (0.5% HPMC) treatment. Other previous studies of this in vivo model have clearly demonstrated enhanced wound healing after topical application of various recombinant human peptide growth factors, with significant synergistic effects observed with specific growth factor combinations (see Brown et al. 1994, J. of Surgical Research, 56: 562-570). Therefore, wound closure data generated during this study were compared to historical positive control data from wounds treated with a combination of recombinant human platelet-derived growth factor-BB (rh-PDGF-BB) and recombinant human transforming growth factor-alpha (rh-TGF-alpha).
[0024] The effects of treatment were studied at both macroscopic and histological levels. At the macroscopic level, treatment methods were examined in terms of (i) the initiation of the repair response of new skin and (ii) wound closure. The initiation of new skin tissue formation was expressed as the number (percentage) of wounds that responded in each group at each time point. Wound closure was examined in terms of the "overall reduction of the remaining open wound area over time" and its components, wound contraction and wound re-epithelialization. At the histological level, wound tissue collected on day 24 was examined and compared in terms of i) granulation tissue deposition (depth), ii) re-epithelialization rate, iii) collagen deposition, and iv) cell proliferation.
[0025] The IMG-1T formulations evaluated in this study (i.e., topical compositions containing sequence ID number: 1 or 2) were found to have a positive effect on wound healing in a db / db diabetic mouse model of impaired wound healing. IMG-1T was found to promote both overall wound closure and its components (contraction and re-epithelialization), and to promote collagen deposition in newly formed granulation tissue.
[0026] At 2 μg / mL, improved wound closure was observed compared to 4 μg / mL, and outcomes tended to improve with 2 μg / mL IMG-1T for all other parameters evaluated.
[0027] material: IMG-1T preparation 1-HIGH - 8 μg / mL - diluted to 4 μg / mL in 0.5% HPMC with sterile water (Ph Eur) in 1% HPMC (Sigma H7509); IMG-1T preparation 2-LOW - 4 μg / mL - diluted to 2 μg / mL in 0.5% HPMC with sterile water (Ph Eur) in 1% HPMC (Sigma H7509); IMG-1T, sterilized with a 0.2 μm filter; Vehicle - 0.5% HPMC (Sigma H7509); Historical positive control (data) - Recombinant human platelet-derived growth factor-BB [rh-PDGF-BB] (Peprotec EC Ltd; 100-14B) + recombinant human transforming growth factor-alpha [rh-TGF-alpha] (Peprotec EC Ltd; 100-16A) in 0.25% HPMC (Sigma H7509). 100 μL was administered to the wounds daily (from day 0 to day 6).
[0028] BKS.Cg-m Dock7 m + / +Lepr db / J Diabetes (healing impairment) mouse model Male diabetic mice (BKS.Cg-m Dock7) approximately 8-9 weeks old m + / +Lepr db(J. Jackson Labs, Bar Harbour, Maine, USA) Thirty mice were acclimatized for one week prior to the start of the study. The animals were maintained in accordance with appropriate regulations and specific requirements for diabetic animals. On day 0, the mice were randomly assigned to one of three treatment regimens (groups 1-3, as described in Table 1 below). [Table 1]
[0029] In short, mice were anesthetized with isoflurane and air, and skin was excised from the dorsal flank according to the protocol and cleaned. A standardized single full-thickness wound (10 mm × 10 mm) was made in the left dorsal flank, approximately 5 mm from the spine. The wound was photographed with an identification plate and calibration rule and then covered with a portion of a transparent film dressing, Tegaderm® film (3M Deutschland GmbH, Germany). The test material (including vehicle control) was then applied directly to the wound surface by injection through the film dressing using a 30 G subcutaneous needle (100 μL dose). All animals were re-anesthetized on post-injury days 4, 8, 12, 16, and 20, the film dressing and free debris were removed, and the wound (and marginal skin) was gently cleaned with gauze soaked in sterile saline. The wound was then evaluated, and digital photographs were taken (with the calibration / identification plate). Tegaderm film dressings were reapplied to all wounds, and the test substance / vehicle was injected into the wound spaces (same as on day 0). After each anesthetic episode, the animals were allowed to recover under warming conditions.
[0030] On day 24 post-injury, the film dressing was removed, the wound was cleaned, evaluated, and digitally photographed. After photographing the wound, blood samples were collected by cardiac puncture, and the animals were subsequently disposed of. Blood samples were collected in dipotassium EDTA tubes, centrifuged at 4°C to produce plasma, and stored at -80°C. One hour before termination, all animals received an ip injection (30 μg / g) of 5-bromo-2'-deoxyuridine (Sigma B5002) in normal saline to facilitate the detection of cell proliferation in histological sections. Subsequently, wound and surrounding marginal tissues were collected from all wounds. The tissues were fixed (neutral buffered formalin, Sigma) and embedded in paraffin wax to facilitate histological examination.
[0031] Wound closure was calculated from magnified and reduced images of the wound taken at each evaluation point using Image Pro Plus image analysis software (version 4.1.0.0, Media Cybernetics, USA). Since the wound closure process arises from the combined effects of wound contraction (movement of marginal tissue inward) and re-epithelialization (re-emergence of the wound due to the movement of epithelial cells inward), wound closure over time was also examined in relation to these factors.
[0032] The following evaluations were performed: the percentage of residual wound area over time, i.e., the area of the open wound remaining at a given time relative to the area of the same wound immediately after injury on day 0; the percentage of wound contraction over time, i.e., the difference between the contracted wound area at a given time and the original wound area, expressed as a percentage of the original wound area; and the percentage of re-epithelialization over time, i.e., the percentage of the original wound area obtained by subtracting the open wound area at a given time from the contracted wound area at that time.
[0033] All wounds in the study were visually evaluated daily until day 8, and then every other day until day 20, to establish their "healing" state. Each wound was scored for whether it showed "neocutaneous tissue formation activity" in the center of the wound area. Scoring was performed independently by two independent observers, and the average percentage of wounds showing "neocutaneous tissue formation activity" at each evaluation point was compared between treatment groups. Neocutaneous tissue formation is thought to have begun when the blood vessels in the fascia at the base of the wound are covered by the "substance" above them. This concealment can be brought about by the formation of cloudy exudate, polymerized / semi-polymerized fibrin, or granulation tissue. Invariably, the first sign of neocutaneous tissue initiation is the formation of reddish exudate within the wound cavity.
[0034] On day 24 post-injury, all animals were painlessly killed using the standard procedure (blood loss was confirmed by cervical dislocation). The wound and surrounding normal tissue were excised, fixed in 10% buffered formalin (Sigma, UK), processed, and embedded in paraffin wax. To facilitate the assessment of cell proliferation, all animals received an ip injection of 5-bromo-2'-deoxyuridine (Sigma B5002) (30 μg / g) one hour prior to termination. The excised tissue was sandwiched between two pieces of foam before being placed in the fixative to reduce tissue curvature. The fixed specimens were trimmed and bisected in the craniocaudal direction, generating two hemisectomies per site. Both halves were processed and embedded in paraffin wax. The specimens were positioned to ensure that appropriate cross-sections of the wound could be obtained. The embedded wounds were cut (6 μm), stained with hematoxylin and eosin, and the stained sections were digitally scanned.
[0035] The sections were stained and evaluated as described below: 1. Hematoxylin and eosin (H&E) facilitate the quantification of granulation tissue formation and re-epithelialization percentage. 2. Anti-BrdU antibody - Visualizes and quantifies proliferating cells in granulation tissue. 3. Visualize the picrosilius red-collagen structure and quantify collagen deposition.
[0036] Measurement of granulation tissue deposition (from the perspective of granulation tissue depth or GTD) Granulation tissue deposition was measured in terms of granulation formation. GTD was measured at nine different sites across the width of each wound using Aperio ImageScope image analysis software (Leica Biosystems, UK). These measurements were averaged to obtain a single granulation tissue depth measurement for each wound studied. Based on the cross-section of the wound area, the GTD distances (d) for the nine different sites included three left-sided epithelialized sites (A), three non-epithelialized sites (C), and three right-sided epithelialized sites (B). Re-epithelialization % was calculated by dividing the sum of the average distances of the epithelialized sites (A+B) by the sum of the average distances of the epithelialized and non-epithelialized sites (A+B+C), and multiplying the resulting ratio by 100.
[0037] Measurement of wound re-epithelialization The degree of re-epithelialization from the left and right edges of each wound was measured using image analysis software Aperio ImageScope (Leica Biosystems, UK) on H&E-stained sections. Wound re-epithelialization was expressed as the percentage of epithelialization on the wound surface.
[0038] Proliferating cells within the wound Proliferating cells within the neodermis and neoepidermal compartments of the wound were specifically detected using BrdU:anti-BrdU immunostaining, as described in Kitano et al. 2001. One hour prior to the end of treatment, all animals received an ip injection (30 μg / g) of 5-bromo-2'-deoxyuridine (BrdU, Sigma). BrdU uptake by proliferating cells was detected in tissue sections by BrdU immunostaining, concurrently with standard ABComplex immunoperoxidase detection techniques. The number of proliferating cells was counted in three wound regions (lateral, intermediate, and central regions). For each region of each wound, two regions of interest (200 × 200 μm each) were selected, and the number of proliferating cells was determined using QuPath software. The mean number of proliferating cells was calculated for each wound as a whole and for each of the three wound regions. These mean values for the whole wound and regions were compared between treatment groups (using appropriate statistical analysis techniques).
[0039] Collagen deposition To visualize collagen deposition within newly formed granulation tissue, sections were stained with picrosilius red (PSR). Collagen deposition was measured in three wound regions (lateral, intermediate, and central). For each region of each wound, two regions of interest (200 × 200 μm each) were selected, and the percentage of the area "occupied" by PSR-stained collagen was determined. The average percentage area of collagen staining was calculated for each wound as a whole and for each of the three wound regions. These averages for the whole wound and regions were compared between treatment groups (using appropriate statistical analysis techniques).
[0040] Residual wound area Each wound was digitally photographed with an identification / calibration plate immediately after injury and on days 4, 8, 12, 16, 20, and 24. For a given wound at any given time point, wound closure was expressed as the ratio of the remaining wound area to the initial wound area immediately after injury (i.e., day 0). The mean percentage data for remaining wound area across all treatment groups are shown in Table 2 below. [Table 2]
[0041] According to the data (Table 2 - above): The "percentage of residual wound area over time" data revealed that wound closure profiles differed among treatment groups (see Figure 1). The highest level of wound closure was observed in the positive control treatment group, and the lowest level was observed in the vehicle control treatment group. The IMG-1T treatment group showed an increased level of wound closure compared to the vehicle control and a decreased level compared to the positive control. Wounds treated with the positive control showed a significant increase in wound closure compared to the vehicle control group from day 4 onward (p ≤ 0.035), and a significantly increased level of wound closure compared to the two IMG-1T treatment groups from day 8 onward (p ≤ 0.023). Wounds treated with IMG-1T [4 μg / mL] showed a significantly increased level of wound closure compared to the vehicle control group from day 8 onward (p ≤ 0.023). Wounds treated with IMG-1T [2 μg / mL] showed significantly increased wound closure from day 8 onward compared to the vehicle control group (p ≤ 0.002). In a comparison of the two IMG-1T treatment groups, increased wound closure was observed at 2 μg / mL compared to 4 μg / mL. This was statistically significant only on day 12 (p = 0.035).
[0042] Contraction is the centripetal movement of the wound edges due to the compression of granulation tissue within the "body" of the wound. The "compressive" force driving this process is thought to be present in fibroblast-type cells. In this study, the contraction percentage was calculated as follows: TIFF2023552515000004.tif19133
[0043] The average percentage of wound shrinkage across all treatment groups is shown in Table 3 (below). [Table 3]
[0044] According to the data shown in Figure 2 using charts (Table 3 - above), the following points became clear: The wound closure profiles of the "wound shrinkage %" data were found to differ significantly between treatment groups, with the lowest level of shrinkage observed in the vehicle control group (see Figure 2). Wounds treated with the positive control (historical data) showed a significant increase in wound shrinkage compared to the vehicle control group from day 4 onward (p ≤ 0.002), and a significant increase in wound shrinkage compared to IMG-1T treated wounds from day 4 to day 16 (p ≤ 0.019), with a similar level of shrinkage observed on day 20 (Figure 2). Wounds treated with IMG-1T [4 μg / mL] showed a significant increase in wound shrinkage compared to the vehicle control group from day 8 onward (p ≤ 0.007), and showed a nearly significant value on day 4 (p = 0.075). Wounds treated with IMG-1T [2 μg / mL] showed a significant increase in wound shrinkage from day 8 onward compared to the vehicle control group (p ≤ 0.002). In a comparison of the two IMG-1T treatment groups, an increase in wound shrinkage was observed at 2 μg / mL compared to 4 μg / mL. This was statistically significant only on day 12 (p = 0.003).
[0045] For a given wound, the area of re-epithelialization at a given time point was expressed as a percentage of the original wound area immediately after injury. The mean wound re-epithelialization rate data for all treatment groups are shown in Table 4 (below). [Table 4]
[0046] According to the data graphically displayed in Figure 3 (Table 4 - above), the following points are clear: Re-epithelialization was first measurable on day 4 post-wound in all groups except the positive control group; the wound closure profiles of the "wound re-epithelialization%" data were found to differ significantly among treatment groups (see Figure 3); wounds treated as positive controls (historical data) showed the following: i. significantly reduced re-epithelialization on day 4 compared to all other treatment groups (p=0.000); ii. significantly increased wound re-epithelialization compared to the vehicle control group from days 8 to 20 (p≦0.015); iii. significantly increased wound re-epithelialization compared to both IMG treatment groups from days 8 to 16 (p≦0.015). Wounds treated with IMG-1T [4 μg / mL] showed a significantly increased rate of wound re-epithelialization on days 16 and 20 compared to the vehicle control group (p ≤ 0.035).
[0047] Evaluations were performed on tissue sections of each wound (collected 24 days post-injury); i) granulation tissue formation (depth), ii) re-epithelialization %, iii) proliferating cell count, and iv) collagen deposition. Granulation tissue deposition (granulation tissue depth, GTD) was measured from digitally magnified x20 photographic microscope scans of H&E sections of each experimental wound (using Aperio ImageScope image analysis software (Leica Biosystems, UK)). These measurements were averaged to obtain a single granulation tissue depth measurement for each wound.
[0048] The following points were revealed from this data: The lowest mean GTD (mean 189.41 μm) was obtained with vehicle-controlled treatment. Treatment with 2 μg / mL and 4 μg / mL IMG-1T resulted in mean GTDs of 237.64 μm and 235.41 μm, respectively. The difference in GTD observed between the two IMG-1T treatment regimens and the difference in GTD observed after vehicle-controlled treatment were not statistically significant. No significant difference in GTD was observed between the two IMG-1T treatment regimens.
[0049] Collagen deposition in each wound was evaluated from tissue sections. Based on collagen deposition data (not shown), the following was revealed: a. In all treatment groups, higher levels of collagen were observed in the lateral and intermediate regions compared to the central region; b. In all wound regions, higher levels of collagen deposition were observed after IMG-1T treatment compared to vehicle control treatment, and this was significant in the lateral and intermediate regions; c. There was a tendency for higher collagen deposition with 2 μg / mL IMG-1T compared to 4 μg / mL.
[0050] The IMG-1T formulation evaluated in Example 1 was found to have a positive effect on wound healing in a db / db diabetic mouse model of impaired wound healing. IMG-1T was found to promote overall wound closure, contraction and re-epithelialization of its components, and collagen deposition in newly formed granulation tissue. Improved wound closure was observed at concentrations of 2 μg / mL and 4 μg / mL.
[0051] Example 2 This exemplary study investigated the effects of three alternative dosing regimens of topically applied IMG-1T in 0.5% HPMC on the repair of full-thickness excised skin wounds in the impaired healing model described in Example 1. Wound healing was examined for wounds treated with IMG-1T (2.0 μg / mL) in 0.5% HPMC applied only on post-wound day 0, and compared to similar wounds treated every four days (i.e., post-wound days 0, 4, 8, and 12) and daily up to post-wound day 6 (a total of seven applications). Wound closure data generated in this study were compared to vehicle-control data from Example 1 (i.e., from wounds exposed to 0.5% HPMC on days 0, 4, 12, and 16).
[0052] As described above, previous studies using this same biological model have clearly shown that wound healing is promoted after topical application of various recombinant human peptide growth factors (Brown et al.). Therefore, the wound closure data created in this study were compared with historical positive control data obtained from wounds treated with a combination of recombinant human platelet-derived growth factor-BB (rh-PDGF-BB) and recombinant human transforming growth factor-alpha (rh-TGF-alpha).
[0053] The effects of treatment were studied at a macroscopic level from the following perspectives: (i) the initiation of the repair response of new skin, and (ii) wound closure. The initiation of new skin tissue formation was expressed as the number (percentage) of responding wounds in each group at each time point. Wound closure was examined in terms of "the overall decrease in the area of remaining open wounds over time," and its components, wound contraction and wound re-epithelialization.
[0054] In this study, a single dose of 100 μL of IMG-1T (2 μg / mL in 0.5% HPMC) administered on day 0 was found to significantly increase the overall wound closure rate compared to vehicle-controlled administration. Considering wound contraction and wound re-epithelialization, which are components of wound healing, this single dose resulted in a decrease in wound contraction while simultaneously significantly increasing re-epithelialization.
[0055] When IMG-1T (100 μL, 2 μg / mL) was administered every four days (E4D), wound closure was significantly increased compared to i) vehicle-controlled treatment (E4D) and ii) IMG-1T administered "only on day 0". This observed increase in wound closure consisted of both a significant increase in wound contraction and an increase in wound re-epithelialization compared to the vehicle-controlled group, suggesting that IMG-1T has a positive effect on both elements of wound closure. In addition, "E4D" administration of IMG-1T significantly increased the percentage of wounds indicating the initiation of wound healing.
[0056] Applying IMG-1T (100 μL, 2 μg / mL) daily for up to day 6 significantly increased wound closure compared to i) vehicle-controlled treatment (E4D), ii) IMG-1T applied only on day 0, and iii) IMG-1T application on E4D. This observed increase in wound closure was confirmed to be due to both increased shrinkage and re-epithelialization. Compared to historical positive controls (also administered daily for up to day 6), overall closure was found to be decreased after treatment with IMG-1T daily for up to day 6. This decrease in overall closure was attributed to substantially lower shrinkage and a substantial but significant increase in the rate of re-epithelialization. The percentage of wounds indicating the initiation of wound healing was found to be the same as that treated with positive controls.
[0057] material: IMG-1T, sterilized with a 0.2 μm filter; IMG-1T - 4 μg / mL in 1% HPMC (Sigma H7509). Diluted to 2 μg / mL in 0.5% HPMC with sterile water (Ph Eur); Historical vehicle control (data) - Example 1; 0.5% HPMC (Sigma H7509); Historical positive control (data) - Recombinant human platelet-derived growth factor-BB [rh-PDGF-BB] (Peprotec EC Ltd; 100-14B) + recombinant human transforming growth factor-alpha [rh-TGF-alpha] (Peprotec EC Ltd; 100-16A) in 0.25% HPMC (Sigma H7509). 100 μL was administered to the wound daily (days 0 to 6).
[0058] The materials and methods used in this study were BKS.Cg-m Dock7 m + / +Lepr db / J This includes the diabetic mouse model described in Example 1. On day 0, mice were randomly assigned to one of three treatment regimens (groups 1-3, as shown in Table 5 below). [Table 5]
[0059] In short, mice were anesthetized with isoflurane and air, and skin was excised from the dorsal flank according to the protocol and cleaned. A standardized single full-thickness wound (10 mm × 10 mm) was created on the left dorsal flank, approximately 5 mm from the spine. The wound was photographed with an identification plate and calibration rule and then covered with a portion of a transparent film dressing, Tegaderm film (3M Deutschland GmbH, Germany). IMG-1T (2 μg / mL in 0.5% HPMC) was applied directly to the wound surface by injection through the film dressing using a 30G subcutaneous needle (100 μL dose). Animals in Group 1 received IMG-1T only on day 0 (immediately after wounding). Animals in Group 2 received IMG-1T on days 0, 4, 8, and 12, and animals in Group 3 received IMG-1T daily from day 0 to day 6 post-wound (a total of 7 applications). All animals were re-anesthetized on days 4, 8, 12, and 16 post-injury, the film dressing and any loose debris were removed, and the wound (and marginal skin) was gently cleaned with gauze soaked in sterile saline. The wound was then evaluated, and digital photographs were taken (along with the calibration / identification plate). Tegaderm® film dressing was reapplied to all wounds, and the test substance was injected into the wound cavity as needed (as on day 0). After each anesthetic episode, the animals were allowed to recover under warming conditions.
[0060] On day 16 post-injury, the film dressing was removed, the wound was cleaned, evaluated, and digitally photographed. After photographing the wound, blood samples were taken by cardiac puncture, and the animals were subsequently disposed of. Subsequently, tissue samples were taken from the wound and surrounding tissues, as well as from the liver and kidneys, from all animals. One hour before termination, all animals received an intravenous injection (30 μg / g) of 5-bromo-2'-deoxyuridine (Sigma B5002) in normal saline to facilitate the detection of cell proliferation in histological sections.
[0061] Each wound was digitally photographed with an identification / calibration plate immediately after injury and on days 4, 8, 12, and 16. For a given wound at any given time point, wound closure was expressed as the percentage of the remaining wound area relative to the initial wound area immediately after injury (i.e., day 0). The mean percentage of remaining wound area for all treatment groups is shown in Table 6 below. [Table 6]
[0062] The raw wound closure data and corresponding wound area percentage data generated during this study are graphically represented in Figure 4. Following a statistical analysis of this data, the following was revealed: The wound closure profiles of the “residual wound area % over time” data differed among treatment groups (see Figure 4). The highest level of wound closure was observed in the positive control treatment group, and the lowest level in the vehicle control group (historical data). The IMG-1T treatment group showed increased levels of wound closure compared to the vehicle control and decreased levels compared to the positive control. Wounds treated with the positive control (historical data) showed significantly increased wound closure compared to the following: i. Wound treatment with vehicle control from day 4 onwards (historical data) (p ≤ 0.035); ii. Wound treatment with IMG-1T "E4D" from day 8 onwards (p = 0.000); iv. Wounds treated with IMG-1T "daily until day 6" on days 12 and 16 (p = 0.000). Wounds treated with IMG-1T "only on day 0" showed significantly increased wound closure compared to wounds treated with vehicle control from days 4 to 12 (historical data) (p ≤ 0.035). Wounds treated with IMG-1T "E4D" showed significantly increased wound closure on days 12 and 16 compared to wounds treated with vehicle control (historical data) (p = 0.000). Wounds treated with IMG-1T daily for the first six days showed a significant increase in wound closure from day four onward compared to vehicle-controlled wounds (historical data) (p=0.000). The following observations were made when comparing different administration frequencies: i. Compared to applying "E4D" only on day 0, closure significantly increased on days 12 and 16 (p=0.000); ii. Applying "daily until day 6" significantly increased closure from day 4 onwards compared to applying "day 0 only" (p≦0.015); iii. Applying "daily until day 6" significantly increased closure from day 4 onwards compared to "E4D" (p≦0.015).
[0063] All three dosing regimens of IMG-1T significantly increased wound closure compared to the historical vehicle-controlled data (E4D). Comparing the three dosing regimens, the greatest increase in wound closure was observed with the "daily until day 6" application, followed by the "E4D" application, and then the "day 0 only" application.
[0064] The raw wound shrinkage data and corresponding wound shrinkage percentage data generated during this study are shown in Table 7 and graphically in Figure 5: [Table 7]
[0065] According to the data in Table 7 (and also shown in Figure 5), the following points are clear: The wound closure profiles of the "wound shrinkage %" data differed significantly among treatment groups, with the highest levels of shrinkage observed in the positive control (historical data) group. Wounds treated with the positive control (historical data) showed significantly increased wound shrinkage from day 4 onward compared to all other treatment groups (p=0.000). Wounds treated with IMG-1T "only on day 0" showed decreased wound shrinkage compared to wounds treated with the vehicle control (historical data). This was statistically significant on day 8 (p=0.029) and nearly significant on day 4 (p=0.052). Wounds treated with IMG-1T "E4D" showed significantly decreased wound shrinkage on day 4 compared to wounds treated with the vehicle control (historical data) (p=0.029). Subsequently, wounds treated with IMG-1T showed increased shrinkage, with a significantly higher shrinkage rate on day 16 compared to vehicle-controlled wounds (p=0.035). Wounds treated with IMG-1T "daily until day 6" showed a significantly reduced wound shrinkage on day 4 compared to vehicle controls (historical data) (p=0.001), and an almost significantly reduced shrinkage on day 8 (p=0.052). Subsequently, wounds treated with IMG-1T showed increased shrinkage, with a significantly higher shrinkage rate on day 16 compared to vehicle-controlled wounds (p=0.002). When comparing different dosing frequencies of IMG-1T, the following observations were made: i. With "E4D" administration, contractions increased from day 8 onwards compared to "day 0 only" administration, and this was statistically significant only on day 16 (p=0.002); ii. On days 12 and 16, "daily until day 6" administration significantly increased contractions compared to "day 0 only" administration (p≦0.035); iii. On days 12 and 16, "daily until day 6" administration slightly increased contractions compared to "E4D" administration, but the difference was not statistically significant.
[0066] For a given wound, the area of re-epithelialization at a given time point was expressed as a percentage of the original wound area immediately after injury. The mean percentage data for wound re-epithelialization for all treatment groups are shown in Table 8 below. [Table 8]
[0067] The data graphed in Figure 6 (Table 8 - above) clearly shows the following: Re-epithelialization was first measurable on day 4 post-wound in all groups except the positive control group. The wound closure profiles of the "wound re-epithelialization%" data were found to differ significantly among the treatment groups (see Figure 6). Wounds treated with positive controls (historical data) showed the following: i. Significantly reduced re-epithelialization on day 4 compared to all other treatment groups (p=0.000); ii. Significantly increased wound re-epithelialization from days 8 to 20 compared to vehicle control treated wounds (p≦0.015); iii. Re-epithelialization rate from day 8 onwards was similar to that of wounds treated with IMG-1T "on day 0 only"; iv. Slightly increased re-epithelialization on day 8 compared to wounds treated with IMG-1T "E4D" (p=0.089), and then remained at the same level; v. Significantly reduced level of re-epithelialization from days 8 to 16 compared to wounds treated with IMG-1T "daily until day 6" (p≦0.029). Wounds treated with IMG-1T "only on day 0" showed significantly increased wound reepithelialization at all time points compared to wounds treated with the vehicle control (p ≤ 0.035). Wounds treated with IMG-1T "E4D" showed significantly increased wound reepithelialization at days 4, 12, and 16 compared to wounds treated with the vehicle control (p ≤ 0.035), and nearly significant at day 8 (p = 0.052). Wounds treated with IMG-1T "daily until day 6" showed significantly increased wound reepithelialization at all time points compared to wounds treated with the vehicle control (p = 0.000).
[0068] When different administration frequencies of IMG-1T were compared, the following results were obtained: i. With "E4D" administration, a similar degree of re-epithelialization was observed compared to "day 0 only" administration, and no significant difference was found; ii. With "daily administration until day 6," the level of re-epithelialization significantly increased from day 4 to day 12 compared to "day 0 only" administration (p ≤ 0.043); iii. With "daily administration until day 6," the level of re-epithelialization significantly increased from day 4 to day 12 compared to "E4D" administration (p ≤ 0.011).
[0069] Every day until day 8, and then every day until day 16, the condition of all wounds was visually evaluated to confirm the state of "healing." Each wound was scored based on whether it showed "neocutaneous tissue regeneration activity" in the wound center. Scoring was performed by two independent observers, and the average percentage of wounds showing "neocutaneous tissue regeneration activity" at each evaluation point was compared between the treatment groups. The following findings were revealed: 1) Of the 10 wounds in the vehicle control group, none showed the initiation of wound healing during the 16-day study period. 2) In the positive control group, all wounds showed a response (i.e., healing began) by day 4 post-inoculation (note that healing initiation data prior to day 4 was not available for this historical control group). This observed response was found to be statistically significant compared to the vehicle control treatment from day 4 onward (p=0.000, Fisher's exact test). 3) Wounds treated with IMG-1T "only on day 0" did not show the formation of new skin tissue during the 16-day study. 4) Wounds treated with IMG-1T "E4D" showed the formation of new skin tissue from day 8 onward, reaching an 80% response rate by day 16. This was significantly higher on days 12-16 compared to vehicle control wounds and wounds treated with IMG-1T "only on day 0" (p ≤ 0.033, Fisher's exact test). 5) In wounds treated with IMG-1T "daily until day 6," new skin tissue was formed in 100% of wounds from day 4 onward. This was comparable to the positive control and significantly greater than in wounds treated with IMG-1T "E4D" from days 4-12 (p ≤ 0.033, Fisher's exact test).
[0070] In Example 2, we investigated the effects of topical application of IMG-1T (2 μg / mL in 0.5% HPMC) according to three administration regimens (only on day 0, every 4 days [E4D], and daily until day 6) on the repair of full-thickness excised skin wounds in db / db diabetic mice with impaired healing. Wound healing treated with IMG-1T (all regimens) was compared to that of vehicle controls treated with E4D. Wound healing data generated during this study were compared to historical positive control data from wounds treated with a combination of recombinant human platelet-derived growth factor-BB (rh-PDGF-BB) and recombinant human transforming growth factor-alpha (rh-TGF-alpha). Wound healing was evaluated over 16 days in terms of (i) the initiation of a new skin repair response and (ii) wound closure. The initiation of new skin tissue formation was expressed as the number of wounds that responded in each group at each time point. Wound closure was examined from both an overall perspective and from the perspective of its constituent components: wound contraction and re-epithelialization. Wound closure (contraction and re-epithelialization) was determined from digital photographs taken at 0, 4, 8, 12, and 16 days post-injury.
[0071] When IMG-1T (2 μg / mL, 0.5% HPMC) was administered as a single 100 μL dose on day 0, the overall rate of wound healing was significantly increased compared to vehicle-controlled administration (E4D application, CICA-IMA-01). Considering wound contraction and wound re-epithelialization, which are components of wound healing, this single dose resulted in a decrease in wound contraction and a significant increase in re-epithelialization. When IMG-1T (100 μL, 2 μg / mL) was administered every 4 days (E4D), wound closure was significantly increased compared to i) vehicle-controlled treatment (E4D) and ii) IMG-1T was administered "only on day 0". This increase in wound closure consisted of both a significant increase in wound contraction and an increase in wound re-epithelialization compared to the vehicle-controlled group, suggesting that IMG-1T has a positive effect on both components of wound closure. Furthermore, administration of IMG-1T "E4D" significantly increased the proportion of wounds indicating the initiation of wound healing.
[0072] When IMG-1T (100 μL, 2 μg / mL) was applied "daily until day 6," wound closure was significantly increased compared to i) vehicle-controlled treatment (E4D), ii) IMG-1T applied "only on day 0," and iii) IMG-1T applied to E4D.
[0073] Example 3 Since collagen is an essential component of wound healing, collagen production in neonatal human epidermal keratinocytes (HEKn) cells treated with IMG-1T containing sequence ID number 1 was measured. After 72 hours of incubation with IMG-1T, HEKn cells were analyzed using the Human Pro-Collagen I Alpha-1 ELISA Kit (AbCam). Increased collagen deposition was observed at low concentrations such as 1% IMG-1T (aqueous solution) (from 10.825 μg / mL collagen in untreated cells to 15.825 μg / mL collagen in cells treated with 1% IMG-1T), with a peak of 20.7 μg / mL collagen production at a concentration of 10% IMG-1T, which is almost double the value in untreated HEKn cells.
[0074] Next, it was determined whether treating HEKn cells with IMG-1T could increase elastin production. After 120 hours of incubation with IMG-1T, HEKn cells were analyzed using the Human Elastin ELISA Kit (AbCam). Similar to collagen deposition, cells cultured in the presence of IMG-1T showed elevated elastin levels, increasing from 2 ng / mL to 2.3 ng / mL in 10% IMG-1T (aqueous solution) (corresponding to an increase of more than 20% in elastin expression).
[0075] These results demonstrate that IMG-1T treatment of keratinocytes (in vitro) dramatically increases both collagen deposition and elastin production by keratinocytes.
[0076] Example 4 Furthermore, IMG-1T can be used for a variety of other skin and wound treatments from both cosmetic and medical perspectives. Skin grafting is a versatile aid for wound closure in burns, trauma, reconstruction, and other large wounds. In split-thickness skin grafts, the surgeon removes a thin layer of skin from a part of the patient's body (donor site) and uses it to close the surgical site on the patient that needs covering (recipient site). Split-thickness skin grafts (STSGs) refer to grafts that, by definition, contain part of the epidermis and dermis, in contrast to full-thickness skin grafts (FTSGs) that consist of the entire epidermis and dermis. Unlike flaps, skin grafts do not have their own blood supply and therefore must rely on a wound bed with sufficient blood vessels for graft survival. Split-thickness skin grafts can be obtained from multiple sources (autografts, homografts, allografts, or xenografts), multiple anatomical locations, and in various thicknesses. Most commonly, STSG autologous grafts are harvested from the lateral thigh or trunk. These sites are aesthetically concealable and easy to harvest due to their large surface area. Split-thickness skin grafts are classified by thickness into thin STSG (0.15-0.3 mm), medium STSG (0.3-0.45 mm), and thick STSG (0.45-0.6 mm). Because the donor site for split-thickness skin grafts retains a portion of the dermis, including dermal appendages, the donor site can regenerate new skin in 2-3 weeks. Therefore, after proper healing, they can be used multiple times, making STSGs versatile for burn surgery and large wounds where donor sites are limited.
[0077] STSG is a very common surgery, but the incidence of infection at the donor site can be a problem, especially regarding infections. This can result in longer postoperative recovery and hospital stays, and increased management costs. In many cases, the healing rate at the donor site is reported to be less than 12 days, although many studies report healing rates of nearly 14-21 days. Within 24 hours, many patients complain of excessive pain, itching, infection, hyperpigmentation, hypopigmentation, hyperpigmentation, and hypertrophic scarring. Furthermore, a significant number of patients develop pathological conditions as late as 6 months post-surgery. Therefore, improving the rate of wound healing and the quality of repair is of paramount importance.
[0078] To test the therapeutic capacity of IMG-1T for non-diabetic wounds, split-thickness wounds were induced in male Danish Landrace X Large White Crossbread pigs. The piglets were anesthetized with isoflurane / oxygen mixed gas supplied through a face mask. A 7x10cm partial wound with a depth of 400mm was made using a dermatome. After incision, the pigs were administered antibiotics (marbosil 10%) for 5 consecutive days. The animals were kept under anesthesia between surgery and medication. This study aimed to evaluate the effect of daily treatment with IMG-1T on the healing of donor wounds. Each pig was exposed to four donor wounds; two wounds received IMG-1T (2ug / mL dose in 1% HPMC gel vehicle), and two wounds received gel vehicle alone. Treated wounds (IMG-1T and vehicle only) were evaluated and treated daily. The area of wound reduction was evaluated every other day using the ARANZ medical device. Wounds treated with IMG-1T showed a significant increase in wound area reduction as early as day 3 post-treatment. Furthermore, tissue examination of newly healed wounds after the end of the study showed that granulation depth increased by more than 25% in animals treated with IMG-1T.
[0079] Example 5 Since collagen is an essential component of wound healing, collagen production in neonatal human epidermal keratinocytes (HEKn) treated with a composition containing sequence ID number:2 was measured. After 72 hours of incubation, HEKn cells treated with the composition containing sequence ID number:2 were analyzed using the Human Pro-Collagen I Alpha 1 ELISA Kit (AbCam). Increased collagen deposition was observed at both concentrations used in Example 3 (8.825 ug / mL for untreated cells, 18.85 and 17.125 ug / mL collagen using IMG-1, and 18.125 and 17.825 μg / mL collagen using IMG-2), with values nearly double that of untreated HEKn cells (see Figure 7). These results indicate that sequence ID number:2 exhibits similar properties to sequence ID number:1 regarding keratinocyte collagen deposition, suggesting its potential as an effective treatment for wound healing.
[0080] Embodiments and their aspects Topical or incisional pharmaceutical compositions comprise an active ingredient, optionally combined with a drug, medicine, or plant (or a combination thereof), and a pharmaceutically acceptable vehicle (or carrier). The pharmaceutically acceptable vehicle (or carrier) may consist of water, oil, alcohol, petrolatum, propylene glycol, glycerin, or a combination thereof, mixed with one or more of the following: preservatives, emulsifiers, absorption enhancers, and fragrances. The combination, ratio, and grade are selected to provide the desired viscosity / spreadability of the finished product.
[0081] First Embodiment The first embodiment relates to a pharmaceutical composition for topical use comprising a therapeutically effective amount of a polypeptide having sequence ID number 1 or 2, or a derivative or analog thereof, and a pharmaceutically acceptable carrier.
[0082] The pharmaceutical compositions disclosed herein may take the form of solutions, creams, ointments, pastes, lotions, foams, sprays, transdermal patches, or gels. Topical formulations are well characterized in the literature (see Benson, et al, Current Drug Deliv. 2019 Jun; 16(5): 444-460; Chang et al, AAPS J. 2015 September 3; 17(6): 1522). Ointments, gels, creams, emulsions, and foams are preferred vehicles for transdermal drug delivery, and IMG-1T can be formulated as an ointment, gel, cream, emulsion, or foam using pharmaceutical methods well known in the art.
[0083] In one embodiment of the first embodiment, a pharmaceutical composition for topical or incisional use comprises a therapeutically effective amount of a polypeptide having sequence ID number: 1 or 2 in a hydroxypropyl cellulose (HPMC) vehicle.
[0084] In one embodiment, HPMCs may be present at concentrations ranging from approximately 0.25% w / v to approximately 2.5% w / v. HPMCs are biocompatible, possess hydrating and gel-forming properties, and are globally approved for use in the preparation of various pharmaceutical formulations. HPMCs are typically used to extend the release time of drugs.
[0085] Cellulose derivative-based hydrogels, such as hydroxypropyl methylcellulose (also known as hypromellose or HPMC), carboxymethylcellulose (CMC), or their salts (e.g., hydroxyethyl methylcellulose (HEMC)), are useful as transdermal drug delivery systems due to their superior properties, including (i) easy application, (ii) reduced systemic side effects, (iii) avoidance of the first-pass effect in the liver, and (iv) improved skin sensation compared to other conventional ointments and patches. Various studies related to the transdermal delivery of different drugs have been reported for cellulose derivative-based hydrogels (see Ciolacu, et al, Cellulose-Based Hydrogels as Sustained Drug-Delivery Systems, Materials 2020, 13, 5270; and Cinie et al, US Patent No. 5,457,093; Lachman et al. The Theory and Practice of Industrial Pharmacy, 1987, Chapter 18 ("Semisolids"), pp. 534-563).
[0086] In one embodiment of the first embodiment, the pharmaceutical composition may be applied topically or incisively, depending on the situation. In yet another embodiment, the pharmaceutical composition may be in the form of a solution, cream, ointment, paste, lotion, foam, spray, transdermal patch, or gel.
[0087] One aspect of the first embodiment relates to a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having sequence ID number 1 or 2, or a derivative or analog thereof, and a pharmaceutically acceptable carrier comprising a cellulose derivative-based hydrogel.
[0088] In one aspect of the first embodiment, the pharmaceutical composition includes sequence ID number 1 or 2 or its derivatives or analogs in amounts ranging from about 0.1 μg / mL to about 10 μg / mL, and all values in that range, for example, amounts ranging from about 0.5 μg / mL, about 1 μg / mL, about 1.5 μg / mL, about 2 μg / mL, about 2.5 μg / mL, about 3 μg / mL, about 3.5 μg / mL, about 4 μg / mL, about 4.5 μg / mL, about 5 μg / mL, about 5.5 μg / mL, about 6 μg / mL, about 6.5 μg / mL, about 7 μg / mL, about 7.5 μg / mL, about 8 μg / mL, about 8.5 μg / mL, about 9 μg / mL, and about 9.5 μg / mL.
[0089] A further aspect of the first embodiment relates to a pharmaceutical composition comprising a polypeptide or its derivative or analog having sequence ID number 1 or 2 in a concentration of about 0.1 μg / mL to about 10 μg / mL, and a pharmaceutically acceptable carrier.
[0090] A further embodiment of the first embodiment relates to a pharmaceutical composition comprising a polypeptide having sequence ID number 1 or 2 in a concentration of about 0.1 μg / mL to about 10 μg / mL and a pharmaceutically acceptable carrier.
[0091] A further embodiment of the first embodiment relates to a topical pharmaceutical composition comprising a polypeptide or derivative thereof having sequence ID number 1 or 2 at a concentration of approximately 2 μg / mL and a pharmaceutically acceptable carrier.
[0092] A further embodiment of the first embodiment relates to a topical pharmaceutical composition comprising a polypeptide having sequence ID number 1 or 2 at a concentration of about 2 μg / mL and a pharmaceutically acceptable carrier.
[0093] In another aspect of the first embodiment, the pharmaceutical composition comprises a sequence ID number: 1 or 2 or its derivatives or analogs in amounts ranging from about 0.01% w / v to about 10% w / v, and all values in that range, for example, ID number 1 or 2, or its derivatives or analogs, and all values in that range, for example, about 0.02% w / v, about 0.03% w / v, about 0.04% w / v, about 0.05% w / v, about 0.06% w / v, about 0.07% w / v, about 0.08% w / v, about 0.09% w / v, about 0.1% w / v, about 0.15% w / v, about 0.2% w / v, about 0.25% w / v, about 0.3% w / v, about 0.35% w / v, about 0.4% w / v, about 0.5% w / v, about 1.0% w / v, about 1.5% Includes w / v, approximately 2% w / v, approximately 2.5% w / v, approximately 3% w / v, approximately 3.5% w / v, approximately 4% w / v, approximately 4.5% w / v, approximately 5% w / v, approximately 5.5% w / v, approximately 6% w / v, approximately 6.5% w / v, approximately 7% w / v, approximately 7.5% w / v, approximately 8% w / v, approximately 8.5% w / v, approximately 9% w / v, and approximately 9.5% w / v.
[0094] A further aspect of the first embodiment relates to a topical pharmaceutical composition comprising a polypeptide having sequence ID number 1 or 2 in an amount of about 0.01% to about 0.1% w / v, or a derivative or analog thereof, and a pharmaceutically acceptable carrier.
[0095] A further aspect of the first embodiment relates to a topical pharmaceutical composition comprising approximately 0.02% w / v of a polypeptide having sequence ID number: 1 or 2 or a derivative or analog thereof, and a pharmaceutically acceptable carrier.
[0096] A further aspect of the first embodiment relates to a topical pharmaceutical composition comprising a polypeptide with sequence ID number 1 or 2 in an amount of about 0.01% w / v to about 0.1% w / v and a pharmaceutically acceptable carrier.
[0097] A further aspect of the first embodiment relates to a topical pharmaceutical composition comprising approximately 0.02% w / v of a polypeptide with sequence ID number 1 or 2 and a pharmaceutically acceptable carrier.
[0098] Second Embodiment A second embodiment relates to a pharmaceutical composition comprising means for promoting wound healing and a pharmaceutically acceptable carrier.
[0099] A first aspect of the second embodiment relates to a pharmaceutical composition comprising means for promoting wound healing and a pharmaceutically acceptable carrier, wherein the means for promoting wound healing is a polypeptide having sequence ID number 1 or 2, or a derivative or analog thereof.
[0100] A second aspect relates to a pharmaceutical composition comprising means for promoting wound healing and a pharmaceutically acceptable carrier, wherein the means for promoting wound healing is a polypeptide having sequence ID number 1 or 2.
[0101] The pharmaceutical compositions disclosed herein exhibit several unexpected properties, such as wound healing, promotion of collagen and / or elastin production in wound tissue, increased wound healing, and improved wound shrinkage and / or wound re-epithelialization.
[0102] Third Embodiment Accordingly, the third embodiment relates to a method for treating wounds in mammals (e.g., humans, human patients, etc.), the method comprising the step of applying a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having sequence ID number: 1 or 2, or a derivative or analog thereof, and a pharmaceutically acceptable carrier, to a wound in a mammal (e.g., humans, human patients, etc.).
[0103] Polypeptides with sequence ID numbers 1 or 2, or their derivatives or analogs, have shown efficacy in the treatment of chronic wounds, including, but not limited to, skin ulcers, infected wounds, ischemic wounds, surgical wounds, radiation-induced skin wounds, or combinations thereof.
[0104] Accordingly, the first aspect of the third embodiment relates to a method for treating wounds in mammals (e.g., humans, human patients, etc.), the method comprising the step of applying a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having sequence ID number: 1 or 2, or a derivative or analog thereof, and a pharmaceutically acceptable carrier, to a wound in the mammal (e.g., humans, human patients, etc.), the wound including skin ulcers, infectious wounds, ischemic wounds, surgical wounds, skin wounds from radiation injury, or combinations thereof.
[0105] Certain skin ulcers are sometimes classified as diabetic foot ulcers. It will be understood that there are several types of diabetic foot ulcers, including (i) neuropathic ulcers (which can occur when there is peripheral diabetic neuropathy but no ischemia due to peripheral artery disease); (ii) ischemic ulcers (which can occur when peripheral artery disease is present but not associated with diabetic peripheral neuropathy); and (iii) neuroischemic ulcers (which can occur when a mammal (e.g., a human) has both peripheral neuropathy and ischemia due to peripheral artery disease).
[0106] Accordingly, one aspect of the third embodiment relates to a method for treating wounds in mammals (e.g., humans, human patients, etc.), the method comprising the step of applying a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having sequence ID number: 1 or 2, or a derivative or analog thereof, and a pharmaceutically acceptable carrier, to a wound in the mammal (e.g., humans, human patients, etc.), the wound including cutaneous ulcers including neuropathic ulcers, ischemic ulcers, neuroischemic ulcers, or combinations thereof.
[0107] Based on the results presented herein and under U.S. Provisional Patent Application No. 63 / 122,746, it will be understood that applying the pharmaceutical compositions of the first or second embodiments to mammals (e.g., humans) may yield several unexpected properties, such as wound healing, promotion of collagen and / or elastin production in wound tissue, increased wound healing, and improvement in wound shrinkage and / or wound re-epithelialization.
[0108] For example, therapeutically effective amounts of polypeptide with sequence ID number: 1 or 2 (i.e., IMG-1T) result in increased collagen production, as measured in an in vitro assay using neonatal human epidermal keratinocytes ("HEKn"). Incubation of HEKn cells with IMG-1T concentrations (approximately 1% w / v to approximately 10% w / v) resulted in a measurable increase in collagen compared to untreated HEKn cells. After 72 hours of incubation with IMG-1T, HEKn cells were analyzed using the Human Pro-Collagen I Alpha-1 ELISA Kit (AbCam). After 72 hours, untreated cells showed a collagen content of approximately 10.8 μg / mL. Increased collagen deposition was observed with approximately 1% w / v IMG-1T (approximately 15.8 μg / mL) and approximately 10% w / v IMG-1T (approximately 20.7 μg / mL). Therefore, the observations showed that applying IMG-1T resulted in an increase in collagen content compared to untreated controls, including, for example, an increase of approximately 45% to 100% in collagen production.
[0109] Accordingly, one aspect of the third embodiment relates to a method for treating wounds in mammals (e.g., humans, human patients, etc.), the method comprising the step of applying a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having sequence ID number: 1 or 2, or a derivative or analog thereof, and a pharmaceutically acceptable carrier, to a wound in a mammal (e.g., humans, human patients, etc.), the application resulting in increased collagen production, which may range from about 45% to about 100% compared to an untreated control.
[0110] After culturing HEKn cells in IMG-1T for 120 hours, they were analyzed using the Human Elastin ELISA Kit (AbCam). Similar to collagen deposition, cells cultured in the presence of IMG-1T showed elevated elastin levels, increasing from 2 ng / mL to 2.3 ng / mL (approximately an 11% increase) with a 10% activator, and to 2.6 ng / mL (approximately a 20% or greater increase in elastin expression) with a 20% activator.
[0111] Accordingly, one aspect of the third embodiment relates to a method for treating wounds in mammals (e.g., humans, human patients, etc.), the method comprising the step of applying a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having sequence ID number: 1 or 2, or a derivative or analog thereof, and a pharmaceutically acceptable carrier, to a wound in a mammal (e.g., humans, human patients, etc.), wherein the application step results in increased elastin production, which may range from about 10% to about 20% compared to an untreated control.
[0112] The results of the HEKn assay show that while IMG-1T may not improve keratinocyte proliferation, it significantly increases the number of CD133 keratinocyte progenitor cells in the cell population and also increases both keratinocyte collagen deposition and elastin production.
[0113] Furthermore, applying a therapeutically effective amount of the polypeptide sequence ID number:1 (i.e., IMG-1T) results in increased wound healing, as measured by studies investigating the rate of remaining wound area, see Table 2 results (see also Figure 1). For example, applying IMG-1T (2 μg / mL) to wounds every 4 days resulted in a significant reduction in remaining wound area compared to untreated controls. Referring to the data in Table 2 (see also Figure 1 and Table 6), it can be seen that applying approximately 2 μg / mL of IMG-1T resulted in a remaining wound area of approximately 1.8% at 24 days, applying approximately 4 μg / mL of IMG-1T resulted in a remaining wound area of approximately 5.9% at 24 days, and the untreated control animals had a remaining wound area of approximately 34% at 24 days.
[0114] Accordingly, one aspect of the third embodiment relates to a method for treating wounds in mammals (e.g., humans, human patients, etc.), the method comprising the step of applying a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having sequence ID number: 1 or 2, or a derivative or analog thereof, and a pharmaceutically acceptable carrier, to a wound in a mammal (e.g., humans, human patients, etc.), the application step results in a reduction of the remaining wound area after 24 days to about 6% or less, including about 5% or less, about 4% or less, about 3% or less, and about 2% or less, compared to an untreated control.
[0115] The data in Table 6 shows that applying IMG-1T daily for the first six days, followed by application every four days, resulted in a significant improvement in the percentage of remaining wound area. Considering the above, it should be understood that the administration schedule may be based on the attending physician's observation, and the pharmaceutical composition may be used as directed. In certain cases, it may be advantageous to prescribe a specific dose of IMG-1T (e.g., 2 μg / mL) with an administration schedule such as twice daily, daily, every other day, every three days, or every four days.
[0116] Accordingly, one aspect of the third embodiment relates to a method for treating wounds in mammals (e.g., humans, human patients, etc.), the method comprising the step of applying a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having sequence ID number: 1 or 2, or a derivative or analog thereof, and a pharmaceutically acceptable carrier, to a wound in a mammal (e.g., a human, a human patient, etc.) on a daily basis.
[0117] Furthermore, another aspect of the third embodiment relates to a method for treating wounds in mammals (e.g., humans, human patients, etc.), the method comprising the step of applying a pharmaceutical composition to a wound in a mammal (e.g., humans, human patients, etc.) comprising a polypeptide having sequence ID number: 1 or 2 in a concentration of about 1 μg / mL to about 10 μg / mL (e.g., 2 μg / mL), or a derivative or analog thereof, and a pharmaceutically acceptable carrier.
[0118] Furthermore, another aspect of the third embodiment relates to a method for treating wounds in mammals (e.g., humans, human patients, etc.), the method comprising the step of applying a pharmaceutical composition comprising a polypeptide with sequence ID number: 1 or 2 in a concentration of about 1 μg / mL to about 10 μg / mL (e.g., 2 μg / mL) and a pharmaceutically acceptable carrier to a wound in a mammal (e.g., humans, human patients, etc.) on a daily basis.
[0119] Another aspect of the third embodiment relates to a method for treating wounds in mammals (e.g., humans, human patients, etc.), the method comprising the step of applying a pharmaceutical composition comprising a polypeptide having sequence ID number: 1 or 2 in a concentration of about 1 μg / mL to about 10 μg / mL (e.g., 2 μg / mL) and a pharmaceutically acceptable carrier to a wound in a mammal (e.g., humans, human patients, etc.) on a daily basis, the pharmaceutical composition being in the form of a solution, cream, ointment, paste, lotion, foam, spray, transdermal patch, or gel.
[0120] Furthermore, applying a therapeutically effective amount of polypeptide sequence ID number:1 or 2 (i.e., IMG-1T) results in increased wound healing, as measured by studies investigating the rate of wound shrinkage, see results in Table 3 (see also Figure 2 and Table 7). For example, applying IMG-1T (2 μg / mL) to wounds every 4 days resulted in substantial shrinkage compared to untreated controls. Referring to the data in Table 3 (see also Figure 2), it can be seen that applying IMG-1T at approximately 2 μg / mL resulted in approximately 68.9% wound shrinkage after 24 days, and applying IMG-1T at approximately 4 μg / mL resulted in approximately 64.7% wound shrinkage after 24 days, while untreated control animals had approximately 43.4% of the wound area remaining after 24 days.
[0121] Accordingly, one aspect of the third embodiment relates to a method for treating wounds in mammals (e.g., humans, human patients, etc.), the method comprising the step of applying a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having sequence ID number: 1 or 2, or a derivative or analog thereof, and a pharmaceutically acceptable carrier, to a wound in a mammal (e.g., humans, human patients, etc.), the application step resulting in a wound shrinkage rate of about 40% or more, including about 65% or more, after 24 days.
[0122] Furthermore, applying a therapeutically effective amount of polypeptide sequence ID number: 1 or 2 (i.e., IMG-1T) results in increased wound healing, as measured by studies investigating improvements in the rate of wound re-epithelialization, see results in Table 4 (see also Figure 3 and Table 8). For example, applying IMG-1T (2 μg / mL) to wounds every 4 days resulted in substantial improvement in wound re-epithelialization compared to untreated controls. Referring to the data in Table 4 (see also Figure 3), it can be seen that applying approximately 2 μg / mL of IMG-1T resulted in approximately 29.3% of the wound area remaining after 24 days, applying approximately 4 μg / mL of IMG-1T resulted in approximately 29.4% of the wound area remaining after 24 days, and the untreated control animals had approximately 22.5% of the wound area remaining after 24 days. Furthermore, the data shown in Table 8 demonstrates that applying 2 μg / mL IMG-1T daily (until day 6) and every four days (E4D) for the remainder of the treatment period resulted in a re-epithelialization rate of approximately 51.6% after 24 days.
[0123] Accordingly, one aspect of the third embodiment relates to a method for treating wounds in mammals (e.g., humans, human patients, etc.), the method comprising the step of applying a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having sequence ID number: 1 or 2, or a derivative or analog thereof, and a pharmaceutically acceptable carrier, to a wound in a mammal (e.g., humans, human patients, etc.), wherein the application step improves the rate of wound re-epithelialization by at least 30% after 24 days.
[0124] It will be understood that further advantages of the pharmaceutical compositions disclosed herein may be derived from the results presented herein.
[0125] Additional features Feature 1. A pharmaceutical composition for promoting wound healing, comprising a therapeutically effective amount of a polypeptide having sequence ID number: 1 or 2, or a derivative or analog thereof, and a pharmaceutically acceptable carrier.
[0126] Feature 2. A pharmaceutical composition according to Feature 1, which is in the form of a solution, cream, ointment, paste, lotion, foam, spray, transdermal patch, or gel.
[0127] Feature 3. A pharmaceutical composition described in any one of the preceding features, wherein the therapeutically effective amount of the polypeptide having sequence ID number 1 or 2, or its derivative or analog, is in the range of approximately 0.1 μg / mL to approximately 10 μg / mL.
[0128] Feature 4. A pharmaceutical composition according to any one of the preceding features, wherein the therapeutically effective amount of the polypeptide having sequence ID number 1 or 2 is in the range of about 0.1 μg / mL to about 10 μg / mL.
[0129] Feature 5. A pharmaceutical composition according to any one of the preceding features, comprising approximately 2 μg / mL of the polypeptide having sequence ID number 1 or 2.
[0130] Feature 6. A pharmaceutical composition comprising means for promoting wound healing and a pharmaceutically acceptable carrier.
[0131] Feature 7. A pharmaceutical composition according to Feature 6, wherein the means for promoting wound healing is a polypeptide with sequence ID number: 1 or 2, or a derivative or analog thereof.
[0132] Feature 8. A pharmaceutical composition according to Feature 6, wherein the means for promoting wound healing is a polypeptide with sequence ID number: 1 or 2.
[0133] Feature 9. A method for treating a wound in a mammal, the method comprising the step of applying a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having sequence ID number: 1 or 2, or a derivative or analog thereof, and a pharmaceutically acceptable carrier, to the wound in the mammal.
[0134] Feature 10. The method of Feature 9, wherein the wound includes a skin ulcer, an infected wound, an ischemic wound, a surgical wound, a skin wound due to radiation injury, or a combination thereof.
[0135] Feature 11. A method according to any one of Feature 9 to 10, wherein the wound is a skin ulcer including a neuropathic ulcer, an ischemic ulcer, a neuroischemic ulcer, or a combination thereof.
[0136] Feature 12. A method according to any one of Feature 9 to 11, wherein the step applied in the preceding stage increases collagen production compared to an untreated control.
[0137] Feature 13. A method according to any one of Feature 9 to 12, wherein the step applied in the preceding stage increases elastin production compared to an untreated control.
[0138] Feature 14. A method according to any one of Feature 9-13, wherein the step applied in the preceding stage increases collagen and / or elastin production compared to an untreated control.
[0139] Feature 15. A method according to any one of Feature 9 to 13, further comprising the step of applying a therapeutically effective amount of human platelet-derived growth factor-BB (rh-PDGF-BB), human transforming growth factor-alpha (rh-TGF-alpha), or a combination thereof to the wound.
[0140] Feature 16. A pharmaceutical composition according to Feature 1, wherein the peptide has at least 95% sequence identity with sequence ID number: 1 or 2, or its derivative or analog, optionally at least 98% sequence identity with sequence ID number: 1 or 2, or its derivative or analog, and optionally at least 99% sequence identity with sequence ID number: 1 or 2, or its derivative or analog.
[0141] Feature 17. A pharmaceutical composition according to any of the preceding features, wherein the pharmaceutically acceptable carrier or vehicle is selected from modified cellulose (such as hydroxypropyl cellulose (HPMC), carboxymethyl cellulose (CMC), or hydroxyethyl methyl cellulose (HEMC)), hypromellose, physiological buffer (such as phosphate-buffered saline), gelatin, or hydrogel.
[0142] Feature 18. A pharmaceutical composition according to any of the preceding features, wherein the pharmaceutical vehicle is present at a concentration of approximately 10% w / w or less, and optionally, the pharmaceutical vehicle is present at a concentration of approximately 5% w / w or less.
[0143] Feature 19. A pharmaceutical composition according to Feature 17, wherein the pharmaceutical vehicle is HPMC, and optionally the HPMC is present in an amount of about 0.5% w / w to about 5% w / w.
[0144] Feature 20. A pharmaceutical composition according to any of the preceding features, wherein the treatment comprises promoting wound healing and / or promoting the production of collagen and / or elastin in wound tissue and / or improving wound shrinkage and / or wound re-epithelialization.
[0145] It will be apparent to those skilled in the art that the features described in relation to any of the embodiments described above are interchangeable between different embodiments. The embodiments described above are examples for illustrating various features of the compositions and methods disclosed herein.
[0146] Throughout this description and claims, the words “comprise” and “contains” and their variations mean “contains, but not limited to,” and they are not intended (and do not exclude) other parts, additives, ingredients, or processes. Throughout this description and claims, the singular encompasses the plural unless the context specifically requires otherwise. In particular, where the indefinite article is used, this specification shall be understood as intending the plural as the singular unless the context otherwise requires otherwise.
[0147] Features, properties, compounds, chemical parts, or groups described in connection with a particular aspect, embodiment, or example will be understood to be applicable to other aspects, embodiments, or examples described herein, insofar as they are incompatible. All features disclosed herein (including the appended claims, abstract, and drawings) and / or all steps of any method or process disclosed herein may be combined in any combination, except for combinations in which at least a portion of such features and / or steps are mutually exclusive. The compositions and methods disclosed herein are not limited to the details of any of the aforementioned embodiments.
[0148] The reader's attention is directed to all papers and documents filed concurrently with or prior to this specification in connection with this application, and to all publicly available papers and documents referenced together with this specification, the contents of all such papers and documents are incorporated herein by reference. For example, the subject matter of U.S. Provisional Patent Application No. 63 / 122,746, filed on 8 December 2020, is incorporated in its entirety by reference.
Claims
1. A pharmaceutical composition for promoting wound healing, comprising a therapeutically effective amount of a polypeptide of SEQ ID NO: 1 or 2, or a derivative or analog thereof, and a pharma- ceutical acceptable carrier.
2. 10. The pharmaceutical composition of claim 1, in the form of a solution, cream, ointment, paste, lotion, salve, foam, spray, transdermal patch, or gel.
3. 2. The pharmaceutical composition of claim 1, wherein the therapeutically effective amount of the polypeptide of SEQ ID NO: 1 or 2, or a derivative or analog thereof, is in the range of about 0.1 μg / mL to about 10 μg / mL.
4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the pharma- ceutically acceptable carrier or vehicle is selected from modified cellulose (such as hydroxypropyl cellulose (HPMC), carboxymethyl cellulose (CMC), or hydroxyethyl methyl cellulose (HEMC)), hypromellose, physiological buffer (such as phosphate buffered saline), gelatin, hydrogel, oil, alcohol, petrolatum, propylene glycol, glycerin, or a combination thereof.
5. 2. The pharmaceutical composition of claim 1, comprising about 2 μg / mL of the polypeptide of SEQ ID NO: 1 or 2, or a derivative or analog thereof.
6. A pharmaceutical composition comprising a means for promoting wound healing and a pharma- ceutically acceptable carrier.
7. 7. The pharmaceutical composition of claim 6, wherein the means for promoting wound healing is a polypeptide of SEQ ID NO: 1 or 2, or a derivative or analog thereof.
8. 7. The pharmaceutical composition of claim 6, wherein the means for promoting wound healing is a polypeptide of SEQ ID NO: 1 or 2, or a derivative or analog thereof.
9. 23. The use of a therapeutically effective amount of a polypeptide of SEQ ID NO: 1 or 2, or a derivative or analogue thereof, and a pharma- ceutically acceptable carrier in the manufacture of a pharmaceutical composition for the treatment of a wound in a mammal.
10. 10. The use of claim 9, wherein the wound comprises a skin ulcer, an infected wound, an ischemic wound, a surgical wound, a skin wound due to radiation injury, or a combination thereof.
11. 10. The use of claim 9, wherein the wound is a skin ulcer, including a neuropathic ulcer, an ischemic ulcer, a neuroischemic ulcer, or a combination thereof.
12. 10. The use of claim 9, wherein the pharmaceutical composition increases collagen production in a mammal to which the pharmaceutical composition is administered, as compared to an untreated control.
13. 10. The use of claim 9, wherein the pharmaceutical composition increases elastin production in a mammal to which the pharmaceutical composition is administered, as compared to an untreated control.
14. 10. The use of claim 9, wherein the pharmaceutical composition increases collagen and / or elastin production in a mammal to which the pharmaceutical composition is administered compared to an untreated control.
15. 10. The use of claim 9, wherein the pharmaceutical composition is applied together with a therapeutically effective amount of human platelet-derived growth factor-BB (rh-PDGF-BB), human transforming growth factor-alpha (rh-TGF-alpha), or a combination thereof.
16. A pharmaceutical composition for topical application comprising a peptide having at least 90% sequence identity to SEQ ID NO: 1 or 2, or a derivative or analog thereof, and a pharmaceutical vehicle.
17. A peptide having at least 90% sequence identity to SEQ ID NO: 1 or 2, or a derivative or analogue thereof, for topical use in promoting wound healing.
18. The pharmaceutical composition of any one of claims 1 to 17, wherein the pharma- ceutically acceptable carrier is HPMC, and optionally, the HPMC is present in an amount of about 0.5% w / w to about 10% w / w.
